[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Gasthuisberg\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":138},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100589795","evaluating-the-impact-of-cryo-analgesia-on-recovery-after-double-lung-transplantation-100589795",false,"NCT06959056","Evaluating the Impact of Cryo-analgesia on Recovery After Double Lung Transplantation","Evaluating the Impact of Cryo-analgesia on Recovery After Double Lung Transplantation: a Pilot Study","CRyoLTRiX","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n3. Bilateral lung transplantation at UZ Leuven\n4. Indication for transplantation: End stage chronic obstructive pulmonary disease (COPD)\n5. Storage of lungs on classic ice, cooled system (LUNGguard® (Paragonix) or X°Port Lung Transport Device (Traferox Technologies Inc.) ) are all permitted\n6. Patients that have undergone lung volume reduction or talcage are not a contraindication for participation in the study.\n\nExclusion Criteria:\n\n1. Unilateral lung transplantation\n2. Lobar transplantation\n3. Donor lung reconditioning using ex-vivo lung perfusion (EVLP)\n4. Combined organ transplantation\n5. Chronic opioid use pre-operatively\n6. Participation in an interventional Trial with an investigational medicinal product (IMP) or device (IMD) that could potentially influence the post-operative outcomes of this study","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this pilot trial is to learn whether the use of cryo nerve block and its effect on sensation in the chest alters recovery after bilateral lung transplantation, and to which extent these parameters are influenced. As this study is setup as a pilot study, the main questions it aims to determine the potential impacted parameters as well as their effect sizes, of cryo-analgesia on both short and long term outcomes following bilateral lung transplantation in COPD patients in a European high volume lung transplant centre.\n\nThe efficacy parameters under evaluation will be:\n\n* is the highest pain score affected by the use of cryo nerve block?\n* Is there an effect on the lung function ?\n* Does cryo nerve block cause specific complications?\n* are patients treated with cryo nerve block still needing the same amount of morphine as a pain killer?\n* is the length of stay in intensive care influenced by the use of cryo nerve block?\n* and is the qualiy of life influenced by the use of cryo nerve block?\n\nParticipants will:\n\n* undergo cryo nerve block or receive routine pain treatment after bilateral lung transplantation\n* be followed up during the first week after the operation, and every month to determine their pain\n* be asked to perform a lung function test and complete quality of life questionnaires 1, 2, 3, 6 months and 1 year after transplantation",[27],"Lung Transplant; Pain",[29,30,31],"cryo nerve block","lung transplantation","cryoanalgesia","RECRUITING","2026-06-04",{"date":35,"type":36},"2026-06-05","ACTUAL",{"date":38,"type":36},"2026-01-04",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"University Hospital, Gasthuisberg","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100543351","improving-endometrial-cancer-assessment-by-combining-genomic-profiling-and-surgical-assessment-100543351","NCT06354738","Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment","Improving Endometrial Cancer Assessment by Combining the New techniqUe of GENomic Profiling With Surgical Extra uterIne disEase Assessment","EUGENIE","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained before any screening procedures\n* Women ≥ 18 years\n* First diagnosis of EC, all disease stages and all histo-types\n\nExclusion Criteria:\n\n* Participant has a history of pelvic or para-aortic lymph node dissection or sampling, previous pelvic (and\u002For para-aortic) radiotherapy, previous neoadjuvant chemotherapy\n* Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol\n* Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Study","FEMALE",{"count":55,"type":21},1000,[24],"EUGENIE is a prospective multicentre interventional study, focused on improving endometrial cancer (EC) assessment by combining the new technique of genomic profiling with surgical extra uterine disease assessment. The investigators aim to correlate EC stage to each of the molecular subgroups of disease and thereby guide surgical treatment and staging of EC by determining the association between molecular classification and disease stage and evaluating if and how disease stage in each of the molecular subgroups associates with prognosis.",[59],"Endometrial Cancer",[59,61,62,63],"Genomic profiling","Molecular classification","Disease staging","2024-04-15",{"date":66,"type":36},"2024-04-17",{"date":68,"type":36},"2023-01-16",{"date":70,"type":21},"2028-11-01",{"name":42,"class":43},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":18,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100082480","effects-of-oncological-treatment-during-pregnancy-on-mother-and-child-100082480","NCT00330447","Effects of Oncological Treatment During Pregnancy on Mother and Child","Oncological Treatment During Pregnancy: Pharmacokinetics of Chemotherapy and Long Term Follow up of the Offspring","Patients do not need to participate in both; however, preferentially both study parts should be performed.\n\n\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*Part I: Pregnancy, delivery and maternal health\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\n\nPatients must meet the following inclusion criteria:\n\n* Histologically proven cancer in association with a pregnancy (during pregnancy or cancer dagnosis within 5 years after pregnancy)\n* \\> 18 years of age, premenopausal\n* Patients who have given their signed and written informed consent to participate in the trial after fully understanding the implication of the protocol\n* Women receiving any cytotoxic drug or radiation therapy during pregnancy are allowed for the assessment of the maternal and fetal outcome (Part II).\n\nExclusion Criteria:\n\n* Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent\n\n\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*Part II: Follow-up of children\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\n\nInclusion Criteria:\n\n\\- Children that were prenatally exposed to cancer of cancer treament. Informed Consent is asked from parents. From the age of 12 years, informed assent is additionally asked from the child. After the age of 18 years, informed consent is solely asked of the offspring.\n\nExclusion Criteria:\n\n* Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent",true,{"count":81,"type":21},5000,"OBSERVATIONAL","The researchers aim to investigate the outcome (overall survival) of mothers who are diagnosed and\u002For treated for cancer during pregnancy. Furthermore they want to test the hypothesis that children who were exposed to cancer or cancer treatment (cytotoxic drugs, radiation therapy, targeted therapy,...) develop normally (neurologic and cardiologic examination).",[85,86],"Cancer","Pregnancy",[88,89,90,91,92,93,94,95,96,97,98,99],"pregnancy","in utero","chemotherapy","radiotherapy","cancer","offspring","neonatal","long term","follow up","cancer during pregnancy","chemotherapy and radiotherapy during pregnancy","long term follow up of children","2024-03-04",{"date":102,"type":36},"2024-03-06",{"date":104,"type":36},"2005-08",{"date":106,"type":21},"2032-12",{"name":42,"class":43},33,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":53,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":120,"studyType":82,"phases":4,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100276448","fertility-preservation-in-young-women-with-cancer-100276448","NCT02878434","Fertility Preservation in Young Women With Cancer","Fertility Preservation in Young Women With Cancer: an International Registration Study From the International Network on Cancer, Infertility and Pregnancy (INCIP)","Inclusion Criteria:\n\n* Young women who want to preserve their fertility during cancer treatment. Patients need to give their signed and written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent","0 Years","40 Years",{"count":119,"type":21},2000,"5 Years","The researchers aim to record the incidence, treatment and long term follow up of fertility preserving cancer treatment. Both the oncological and fertility outcome are recorded.\n\nStudy population: All patients with a cancer for whom a fertility preserving cancer treatment is applied. The results of the study population are compared to young women undergoing standard cancer treatment.",[85,123],"Fertility",[85,123,86,125,126,127,128],"Chemotherapy","Radiotherapy","Long term","Follow up","2020-11-17",{"date":131,"type":36},"2020-11-18",{"date":133,"type":36},"2017-05-23",{"date":135,"type":21},"2032-07",{"name":42,"class":43},2,""]